All News


All series


All All News

Early results for a new agent, pyrotinib (HTI-1001), are showing promise for the treatment of HER2-positive breast cancer, according to phase 1 results from China published in the Journal of Clinical Oncology, which showed that the drug was well-tolerated and showed anti-tumor activity.

Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/refractory follicular lymphoma who had at least two therapies beforehand, according to Bayer, the manufacturer of the drug.

Knowing that parents of critically ill infants in the neonatal intensive care unit (NICU) receive a specific set of nursing-based supports, a team of nurses at UC Irvine Health in Huntington Beach, California, set out to find out whether lessons from the NICU can be applied in the inpatient oncology setting and developed an evidence-based protocol modeled on the NICU experience.

There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the drug to treat follicular lymphoma in the first-line setting, according to results from the phase 3 SABRINA trial that were published in The Lancet Haematology.